Fig. 6.

NF-κB activity. Peripheral blood monocytes isolated from nonpregnant (NP), normotensive pregnant (NT), and preeclamptic (PE) women were treated with or without an NF-κB inhibitor BAY 11–7085 (a) or α7nAChR agonist PNU-282987 (b) for 24 h, then the DNA binding activity of NF-κB was measured. **p < 0.01 vs. the vehicle group of the NP and NT groups; ^##p < 0.01 vs. the PE group treated with vehicle (two-way ANOVA followed by Bonferroni post-test, groups of NP, NT and PE were entered as the between-subjects factor, treatments of vehicle and BAY 11–7085 or PNU-282987 were entered as the within-subjects factor)